{
    "id": 30939,
    "fullName": "LY75 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "LY75 positive indicates the presence of the LY75 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4065,
        "geneSymbol": "LY75",
        "terms": [
            "LY75",
            "CD205",
            "CLEC13B",
            "DEC-205",
            "GP200-MR6",
            "LY-75"
        ]
    },
    "variant": "positive",
    "createDate": "09/11/2019",
    "updateDate": "09/11/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18451,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEN1309 treatment reduced tumor volume in a cell line xenograft model of diffuse large B-cell lymphoma with heterogeneous LY75 expression (PMID: 31227646).",
            "molecularProfile": {
                "id": 33235,
                "profileName": "LY75 positive"
            },
            "therapy": {
                "id": 8717,
                "therapyName": "MEN1309",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16207,
                    "pubMedId": 31227646,
                    "title": "MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227646"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18453,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEN1309 reduced tumor volume in patient-derived xenograft (PDX) models of triple-negative breast cancer with low and high level of LY75 expression, and inhibited tumor growth and induced tumor regression in cell line xenograft models with low level LY75 expression (PMID: 31227646).",
            "molecularProfile": {
                "id": 33235,
                "profileName": "LY75 positive"
            },
            "therapy": {
                "id": 8717,
                "therapyName": "MEN1309",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16207,
                    "pubMedId": 31227646,
                    "title": "MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227646"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18460,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEN1309 reduced tumor volume in a cell line xenograft model of LY75-positive bladder carcinoma and in patient-derived xenograft (PDX) models with heterogeneous LY75 expression (PMID: 31227646).",
            "molecularProfile": {
                "id": 33235,
                "profileName": "LY75 positive"
            },
            "therapy": {
                "id": 8717,
                "therapyName": "MEN1309",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16207,
                    "pubMedId": 31227646,
                    "title": "MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227646"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18458,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEN1309 reduced tumor volume in patient-derived xenograft (PDX) models of pancreatic adenocarcinoma with low and high level of LY75 expression, and decreased tumor volume and induced tumor regression in a cell line xenograft model with high level of LY75 expression (PMID: 31227646).",
            "molecularProfile": {
                "id": 33235,
                "profileName": "LY75 positive"
            },
            "therapy": {
                "id": 8717,
                "therapyName": "MEN1309",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16207,
                    "pubMedId": 31227646,
                    "title": "MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31227646"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 33235,
            "profileName": "LY75 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}